Mr. Butler has more than 25 years of drug development and leadership experience in the biopharmaceutical industry. Mr. Butler joined Halozyme in November 2017 as Vice President, Clinical Development Operations. In this role he was accountable for the successful execution and conduct of all Halozyme global oncology studies, including data quality and readiness for data analysis.
In November 2019 he assumed the role of Chief of Staff to the CEO, Vice President, Head of Project Management with accountability to oversee overall operational effectiveness. Prior to Halozyme, Mr. Butler served as Executive Director of Clinical Operations at MEI Pharma, Inc., an oncology-based clinical development pharmaceutical company, where he led the efforts of the execution of global clinical trials. Prior to joining MEI Pharma, Mr. Butler held positions of increasing responsibility and leadership at other various biopharmaceutical companies, including Prometheus Laboratories (a Nestlé Health Science subsidiary), Shire Pharmaceutical, Inc., Pfizer, Inc., and Otsuka America Pharmaceutical, Inc. Mr. Butler also held the position of Regional Director at Covance, Inc., a global Clinical Research Organization (CRO) where he provided strategic and tactical planning across the company’s multiple Clinical Research units.
Mr. Butler received his B.S. in Biology from Butler University and certification in a leadership program through the Center for Management Development at London Business School.